AN2 Therapeutics, Inc.
- ANTX
- NASDAQ
- Biotechnology
- Infectious Disease Therapies
- Clinical-Stage Biopharma
- Oral Antibiotics
$3.38
Today −6.11%Quote Oct 16, 2026, 08:00 PM UTC
−31.02%over the last month
Max drawdown −40.8%From 1-month high −40.8%3 months −29.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$127.5M
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$9.00
+166.3% from here
Floor
$3.24
4.1% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ANTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
21